HOOKIPA Pharma prices $75M public offering of common stock and convertible preferred stock

HOOKIPA Pharma Inc.

Issued 21.7M common shares at $2.00/share and 15,800 Series A-1 convertible preferred shares at $2,000 each (each convertible into 1,000 common shares).
Gross proceeds $75M; net proceeds expected ~$70M after underwriting discounts and expenses.
Offering expected to close March 4, 2022; underwriters have 30-day option for up to 5.625M additional common shares.
After offering, shares outstanding will be 50,868,668, excluding the underwriters' option.
SVB Leerink and RBC Capital Markets acted as joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.